Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
Phase 1
Completed
- Conditions
- Stage IV MelanomaStage III Melanoma
- Interventions
- Drug: IMP321 (eftilagimod alpha)
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Immutep Australia Pty. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02676869
- Locations
- 🇦🇺
Royal Brisbane Womens Hospital, Brisbane, Queensland, Australia
🇦🇺Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺Greenslopes Private Hospital, Brisbane, Queensland, Australia